Cagri Kiziltunc

Cagri Kiziltunc

Auto-generated profile, based on publicly available information

Cagri Kiziltunc


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2023 in Diseases
Verified
Journal Article
Open access
PDF file
EEERAY ERGE
ERAY ERGE
CKCagri Kiziltunc
Cagri Kiziltunc
Sumeyye Buse BalciSumeyye Buse Balci
Sumeyye Buse Balci
BTBurcin Atak Tel
Burcin Atak Tel
SBSatilmis Bilgin
Satilmis Bilgin
Gulali AktasGulali Aktas
Gulali Aktas
Background: Hashimoto’s thyroiditis (HT) is a chronic autoimmune thyroiditis that causes systemic inflammation in the body, leading to hypothyroidism and an enlargement of the thyroid gland. Objectives: This study aims to reveal whether there is a relationship between Hashimoto’s thyroiditis and the platelet-count-to-lymphocyte-count ratio (PLR), which is used as a new inflammatory marker. Methods: In this retrospective study, we compared the PLR of the euthyroid HT group and the hypothyroid-thyrotoxic HT group to the controls. We also evaluated the values of thyroid-stimulating hormone (TSH), free T4 (fT4), C-reactive protein (CRP), aspartate transaminase (AST), alanine transaminase (ALT), white blood cell count, lymphocyte count, hemoglobin, hematocrit, and platelet count in each group. Results: The PLR of the subjects with Hashimoto’s thyroiditis was found to be significantly different from the control group (p < 0.001), with the rankings as follows: hypothyroid-thyrotoxic HT 177% (72–417) > euthyroid HT 137% (69–272) > control group 103% (44–243). In addition to the increased PLR values, an increase in CRP values was also observed, revealing a strong positive correlation between the PLR and CRP in the HT patients. Conclusion: In this study, we found out that the PLR was higher in the hypothyroid-thyrotoxic HT and euthyroid HT patients than in a healthy control group.

3 October 2025 in Medicine
Verified
Journal Article
Open access
SSSuat Sincan
Suat Sincan
GSGülden Sincan
Gülden Sincan
ISİsTemi Serin
İsTemi Serin
ÇKÇağri Kiziltunç
Çağri Kiziltunç
SASeda Aşkin
Seda Aşkin
Vascular endothelial growth factor (VEGF) plays a critical role in increasing the release of pro-inflammatory cytokines, endothelial cell proliferation, and regulating vascular permeability in COVID-19 cases. p53 regulates cellular stress responses. However, the precise interplay and prognostic significance of p53 and vascular endothelial growth factor in the context of COVID-19 pathogenesis and disease progression, particularly concerning mortality outcomes, remain to be fully elucidated. We investigated vascular endothelial growth factor and p53 levels in COVID-19 patients and examined the relationship of these markers with the clinical course and prognosis of the disease. A total of 30 patients with COVID-19 and 30 individuals in the control group were examined. The clinical symptoms, laboratory parameters, and survival status of COVID-19 patients participating in the study were recorded. Vascular endothelial growth factor and p53 levels were analyzed using the ELISA method. A P -value of < 0.05 was considered statistically significant in statistical analyses. p53 levels were significantly higher in COVID-19 patients (859.19 ± 385.43 ng/L) compared to the control group (727.29 ± 440.49 ng/L) ( P = .04). There was no significant difference in vascular endothelial growth factor levels between the patient (126.52 ± 75.7 ng/L) and control groups (169.2 ± 112.3 ng/L) ( P = .22). In deceased patients, both p53 and vascular endothelial growth factor levels were significantly higher than in the control group ( P < .001, P = .03, respectively). This study supports the prognostic roles of p53 and vascular endothelial growth factor levels in COVID-19 disease.